首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Rationale design and methodology of a double-blind randomized placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)
【2h】

Rationale design and methodology of a double-blind randomized placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

机译:艾司西酞普兰预防急性冠脉综合征抑郁症的双盲随机安慰剂对照研究的原理设计和方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome.
机译:背景急性冠状动脉综合征(即心肌梗塞和不稳定型心绞痛)患者的抑郁症患病率高于一般人群。焦虑症的患病率也更高。抑郁和焦虑都与不良的心脏预后和较高的死亡率有关。急性冠状动脉综合征患者的合并抑郁症经常无法诊断,因此,预防这种危险因素是一项艰巨的任务。冠状动脉疾病抑郁症(DECARD)的研究旨在检查急性冠状动脉综合征患者是否有可能预防抑郁症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号